2 Products
ADTUK
Your Current Vehicle
Or
Select Your Vehicle
Popular Part Types
Only part types stocked for this brand are shown.
Car Parts Categories
Browse the main catalogue areas in which this brand has matching products.
Other popular manufacturers of aftermarket automotive parts
Explore established alternatives with related products in the current catalogue.
ADTUK: understand the range before choosing
ADTUK supplies oral-fluid drug-testing products. The two entries have different evidential roles: an ALLTEST six-panel lateral-flow saliva screen, live code DSD865, and a collection pack for laboratory mass-spectrometry confirmation with chain-of-custody documentation. A rapid result is presumptive and must not be described as a medical diagnosis, impairment measurement or confirmed positive.
AutoMotoPart currently lists 2 ADTUK items. The largest ADTUK groups are 2 site safety entries. ADTUK totals can change, so a category count is orientation rather than proof that a particular reference suits a vehicle, workplace or job. The exact ADTUK listing, its current technical information and the item in front of you must agree.
What the ADTUK page actually covers
| Product group in this range | Current entries | Selection focus |
|---|---|---|
| Site Safety | 2 | Use the rapid six-panel device only for presumptive screening and the documented laboratory pack for specified confirmatory analysis under a lawful workplace policy. |
Both entries are Site Safety products but not equivalent kits. The Alltest item produces an on-site visual screen in minutes. The laboratory item is a specimen-collection and chain-of-custody service with a later analytical report. Neither product alone defines employer authority, consent, privacy, cut-offs or disciplinary procedure.
Build a reliable shortlist
Define the purpose before selecting a test: immediate safety triage, policy screening or confirmation of a non-negative screen. Identify the drug groups, cut-offs, detection window, specimen type, laboratory method, accreditation scope, turnaround and how results will be reviewed without making unsupported impairment conclusions.
| Check | Why it matters | Useful evidence |
|---|---|---|
| Purpose | Screening and confirmation answer different analytical questions | Written policy, risk basis and decision pathway |
| Panel | Six-panel wording does not identify every analyte or cut-off | Exact DSD865 foil, IFU and lot documentation |
| Collection | Food, drink, timing, sample volume and handling affect validity | Trained collector and exact oral-fluid procedure |
| Confirmation | Mass spectrometry and accreditation must cover the target matrix/analytes | Laboratory scope, cut-offs, uncertainty and chain of custody |
| Employment | A result can have serious personal consequences | Consent, policy, HR review, appeal and medical review route |
| Privacy | Drug-test data is sensitive health information | DPIA, access control, transparency, retention and secure disposal |
Do not buy a six-panel kit before confirming which six drug groups and cut-offs that exact variant contains. Similar DSD series devices can use different methadone, methamphetamine or other panels, so the IFU and foil printing must control.
Rapid oral-fluid results are presumptive
Check the sealed device, lot, expiry, storage conditions and exact six analytes before collection. Follow restrictions on eating, drinking, smoking or oral products for the stated pre-collection period. Use the supplied collector and dispenser exactly, add the specified sample volume and start timing immediately. Read only inside the IFU window; a late reading is not a valid result.
Verify the control indicator first. An absent control makes the test invalid regardless of test lines. Follow the maker's line-interpretation rule, including faint lines, without subjective strengthening. Record negative, non-negative or invalid rather than positive diagnosis. Photographing or retaining the device must be authorised by the privacy policy and cannot replace contemporaneous records.
Cut-offs do not measure impairment
A cut-off is the concentration used by the test to classify an analytical response. Home Office guidance explicitly warns that analytical cut-offs are not impairment thresholds. A non-negative result does not show when a substance was taken, how much was used, whether it was prescribed or whether the person is currently unsafe; a negative result does not prove absence below cut-off or outside the detection window.
Collect relevant medication information through a confidential, purpose-limited route and avoid managers making clinical interpretations. Cross-reactivity and legitimate medicines may need medical review. If a person appears impaired or creates immediate risk, remove them from safety-critical activity under the policy and obtain appropriate medical or emergency help without waiting for a screening device.
Confirmation requires scope and chain of custody
UKAS explains that presumptive screening is qualitative, while confirmatory analysis uses a secondary method such as mass spectrometry with qualifier-ion identification. Confirmatory results depend on the named laboratory's accredited scope for oral fluid, target analytes and method. GC/MS, LC-MS/MS and other mass-spectrometry methods should not be treated as interchangeable marketing terms without the report.
Use tamper-evident containers, donor and collector identifiers, witnessed seals, times, signatures and controlled transfer. Document every person who handles the specimen and any temperature or transport requirements. A broken seal, mismatched identifier, insufficient volume or unexplained custody gap must be resolved rather than hidden. Preserve a split-sample or review route when the programme requires it.
Consent, fairness and data protection
HSE says employees must consent to screening and that testing should form part of the overall health and safety policy. The policy should explain who may be tested, triggers or genuine random selection, substances, specimen, consequences, refusal route, support and confirmation. Consultation and consistent application reduce arbitrary or discriminatory decisions.
ICO guidance requires a clear purpose, necessity and proportionality, often documented through a data protection impact assessment. Tell workers what is collected and why, who receives it, retention and rights. Limit testing to relevant groups and substances, avoid covert samples, secure results and disclose only what decision-makers genuinely need. Physical consent does not by itself supply every UK GDPR lawful basis.
Interpret and communicate results carefully
A trained responsible person should check device validity and laboratory documentation, then apply the written policy. Do not tell colleagues that someone tested positive when only a non-negative screen exists. Pause irreversible employment action pending confirmation, expert interpretation and the agreed appeal or medical-review process.
The live DSD865 record says five-minute reading and more than 99% accuracy, but those statements require the exact current IFU, lot and analyte validation before publication. Accuracy varies with drug, cut-off, comparator and sample conditions. Keep records factual: kit, lot, expiry, panel, collection, result category, confirmation outcome and authorised decision.
From identification to a checked result
| Stage | Good practice for this range | Mistake to avoid |
|---|---|---|
| Govern | Set lawful purpose, consent, privacy, cut-offs and consequence pathway | Buying kits before a defensible workplace policy |
| Collect | Use trained staff, valid lot, correct timing and donor safeguards | Covert, contaminated or undocumented sampling |
| Screen | Check control and report negative, non-negative or invalid | Calling a lateral-flow response a confirmed positive or impairment |
| Confirm | Use sealed chain-of-custody specimen and accredited scope | Taking disciplinary action from an unconfirmed screen |
| Review | Use medical/technical interpretation, privacy and fair appeal | Sharing sensitive results broadly or retaining indefinitely |
Audit every programme, collector and laboratory periodically. Keep current IFUs, training, quality-control records, laboratory accreditation scope, chain-of-custody forms, DPIA and retention schedule available for review.
Reading real ADTUK references
The ADTUK names below are examples from the current range and show why the complete description matters. They are not universal ADTUK recommendations and should not be treated as a fitment list. Within ADTUK, a shared family word can conceal a different dimension, connector, material, pack format, operating condition or installation side.
| Example listing | What to verify beyond the name |
|---|---|
| Alltest 6 Panel Saliva Drug Testkit | DSD865 exact six analytes, cut-offs, collector/dispenser parts, control rule, read window, expiry and IFU validation |
| Saliva Laboratory GC/MS confirmation drug test | Laboratory saliva pack, donor consent, sealed chain of custody, specified analytes, UKAS scope, MS method and reporting cut-offs |
The on-site kit and laboratory service are a sequence, not competing claims of certainty. A rapid screen is presumptive; a laboratory report confirms only the substances and thresholds within its requested and accredited scope.
Common errors around ADTUK products
- Calling a non-negative rapid screen a confirmed positive.
- Using analytical cut-offs as proof of impairment or driving illegality.
- Publishing over 99% accuracy without analyte-specific official validation.
- Reading a cassette outside the exact IFU time window.
- Ignoring prescriptions, cross-reactivity or invalid control results.
- Testing without justified policy, worker knowledge and physical consent.
- Breaking chain of custody or using a laboratory outside accredited scope.
- Sharing health information widely or retaining it without necessity.
ADTUK questions and answers
Q: What are the two ADTUK products?
A: A six-panel oral-fluid screening kit and a chain-of-custody saliva laboratory confirmation pack.
Q: Is a rapid screen diagnostic?
A: No. It is a presumptive analytical screen, not a medical diagnosis or impairment assessment.
Q: What does non-negative mean?
A: The screen did not meet its negative rule for a panel and needs policy-defined confirmation and review.
Q: Does a negative prove no drug use?
A: No. Concentration may be below cut-off, outside the detection window or affected by collection factors.
Q: Does a cut-off prove impairment?
A: No. Official Home Office guidance says analytical cut-offs are not impairment thresholds.
Q: Is the kit more than 99% accurate?
A: Do not make that blanket claim without the exact DSD865 IFU and analyte-specific validation conditions.
Q: When should the result be read?
A: Only at the time window printed in the exact current IFU; the live five-minute wording needs verification.
Q: Why confirm a non-negative screen?
A: Mass-spectrometry confirmation provides more specific identification under controlled laboratory methods.
Q: Is GC/MS always the confirmation method?
A: Check the actual laboratory report; services may use GC/MS, LC-MS/MS or another accredited method.
Q: What is chain of custody?
A: A documented, sealed record of collection, identity, transfer, receipt and handling that protects specimen integrity.
Q: Must a worker consent?
A: HSE says employees must consent to workplace screening for practical and legal reasons within a proper policy.
Q: How should results be stored?
A: As restricted sensitive health information with a defined purpose, access controls and justified retention.
